Feature | June 05, 2014

Proton Beam Therapy Model Policy Issued by ASTRO

Provides guidance on appropriate coverage for radiation treatment

June 5, 2014 — The American Society for Radiation Oncology (ASTRO) has issued a new model policy for proton beam therapy (PBT) that details which cancer diagnoses meet ASTRO’s evidence-based standards and should be covered by private insurers and Medicare. Developed by leading radiation oncologists and medical physicists, including significant input from expert representatives in proton therapy, this model policy supports PBT coverage for appropriate patients and identifies areas where coverage with evidence development and further research are needed.

PBT is neither a new nor an experimental technology for treating cancer with radiation. It utilizes proton radiation particles to deliver highly conformal radiation therapy to a specific tumor target area while giving a much lower dose to the normal tissues in the proton beam’s path of entry and exit. PBT’s reduced radiation dose to healthy tissues is attractive because it can reduce side effects for patients, which potentially increases their quality of life. To date, scientific evidence exists confirming that PBT is particularly useful in a number of pediatric cancers, particularly those in the brain, as well as for certain adult cancers such as ocular melanoma. Additional research on other cancer disease sites, such as breast, prostate and lung, is ongoing with NCI-supported clinical trials currently accruing patients in all three disease sites at the more than 14 proton therapy treatment centers around the country. PBT has attracted significant attention due to its relative cost, which can be dramatically more than traditional external beam radiation therapy due to the significant expense of building and maintaining proton therapy centers.

“Proton beam therapy is demonstrating promise in our continuing efforts to improve survival and cure rates for cancer patients while reducing side effects,” said Colleen A.F. Lawton, M.D., FASTRO, chair of ASTRO’s Board of Directors. “As the leading experts in radiation oncology, it is important for ASTRO to provide balanced, evidence-based guidance to payers that ensures access to PBT for cancer patients while being judicious stewards of our nation’s and our patients’ financial resources.”

This model policy recommends two coverage groups for PBT: 1) patients with specific diagnoses for which PBT has been proven to be effective; and 2) patients with cancer diagnoses where evidence of effectiveness of PBT is still emerging, and therefore coverage with evidence development is recommended for patients if they are enrolled in clinical trials or a multi-institutional registry to collect data and inform consensus on the role of proton therapy. This model policy is consistent with ASTRO’s previous statement on the use of PBT for prostate cancer, as well as ASTRO’s Choosing Wisely list issued last September. In addition, ASTRO urges private insurers and Medicare to cover PBT for cancer patients with difficult-to-treat, rare or highly complex cases for which the characteristics of PBT offers advantages over other forms of treatment.

ASTRO model policies are developed to communicate what ASTRO believes are correct coverage policies for radiation oncology. The ASTRO model policies do not serve as clinical guidelines, and they are subject to periodic review and revision. The ASTRO model policies may be reproduced and distributed, without modification, for noncommercial purposes. ASTRO has previously issued model policies on coverage for brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS), and they are available online at www.astro.org/ModelPolicies.

The PBT model policy was approved by ASTRO’s Board of Directors on May 20, 2014, and is available online atwww.astro.org/protonmp.

For more information: www.astro.org

Related Content

CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones
News | Radiation Therapy | July 05, 2019
Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of...
Civco Displaying Universal Couchtop ProForm Head & Neck Solution at AAPM
News | Patient Positioning Radiation Therapy | July 03, 2019
The upcoming release of Civco’s Universal Couchtop ProForm Head & Neck Solution will allow proton therapy centers...